ArticlePloS one2015
Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review.CNS drugs · 2020Pooled it
- Article
- Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.Journal of neurology · 2024Observational
- Article
- Article
- Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis.Caspian journal of internal medicine · 2022Article
- Cognitive Dysfunction in the Early Stages of Multiple Sclerosis-How Much and How Important?Current neurology and neuroscience reports · 2020Review
- Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease.Therapeutic advances in neurological disorders · 2020Review
- Reduction of integrin alpha 4 activity through splice modulating antisense oligonucleotides.Scientific reports · 2019Article
- Mechanisms of neurobehavioral abnormalities in multiple sclerosis: Contributions from neural and immune components.Clinical neurophysiology practice · 2019Review
- Observational
- Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.Neural regeneration research · 2018Review
- Estriol-mediated neuroprotection in multiple sclerosis localized by voxel-based morphometry.Brain and behavior · 2018Article
- Baseline biomarkers of connectome disruption and atrophy predict future processing speed in early multiple sclerosis.NeuroImage. Clinical · 2018Article
- Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis.Current neuropharmacology · 2018Review
- Sleep-Disordered Breathing in People with Multiple Sclerosis: Prevalence, Pathophysiological Mechanisms, and Disease Consequences.Frontiers in neurology · 2017Review
- Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study.Frontiers in neurology · 2017Article
- Article
- Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.Journal of neurology · 2016Article
- Association between speech rate measures and cognitive function in people with relapsing and progressive multiple sclerosis.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies reported that Multiple Sclerosis (MS) patients treated with natalizumab for one or two years exhibit a significant reduction in relapse rate and in cognitive impairment, but the long term effects on cognitive performance are unknown. This study aimed to evaluate the effects of natalizumab on cognitive impairment in a cohort of 24 consecutive patients with relapsing remitting MS treated for 3 years. The neuropsychological tests, as well as relapse number and EDSS, were assessed at baseline and yearly for three years. The impact on cortical atrophy was also considered in a subgroup of them, and are thus to be considered as preliminary. Results showed a significant reduction in the number of impaired neuropsychological tests after three years, a significant decrease in annualized relapse rate at each time points compared to baseline and a stable EDSS. In the neuropsychological assessment, a significant improvement in memory, attention and executive function test scores was detected. Preliminary MRI data show that, while GM volume did not change at 3 years, a significantly greater parahippocampal and prefrontal gray matter density was noticed, the former correlating with neuropsychological improvement in a memory test. This study showed that therapy with Natalizumab is helpful in improving cognitive performance, and is likely to have a protective role on grey matter, over a three years follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.